Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBioPharma Dive ↗
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that…
The WeekPharmaVoice ↗
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to ac…
The WeekFiercePharma ↗
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing c…
The WeekFierceBiotech ↗
AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for ch…
The WeekBriefing
Lisraya won FDA approval on August 27 as the first oral drug indicated for dermatomyositis in adults. The labe…
The WeekPharmaceutical Technology ↗
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Thera…
The WeekBioPharma Dive ↗
What's possible when AI models can learn from additional health data modalities to create a more complete unde…
The WeekPharmaVoice ↗
How risk prediction is making early intervention trials in MASLD more feasible.…
The WeekSTAT News ↗
The latest study on CTE in football players "quantifies but does not reveal a problem," writes Emily Harrison,…
The WeekFiercePharma ↗
After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis' antisense oligonucleotide Wainua,…
The WeekFierceBiotech ↗
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotec…
The WeekBriefing
Takeda won FDA approval for Mimrylo on August 28, 2026, giving polycythemia vera patients a first-in-class opt…
The WeekFiercePharma ↗
The FDA has approved Takeda's Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the n…
The WeekFierceBiotech ↗
Following Merck and Moderna's phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a simil…
The WeekBriefing
Two months after pairing his second SPAC with Talawar Therapeutics, Someit Sidhu returned with another biotech…
The WeekSTAT News ↗
A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's h…
The WeekSTAT News ↗
Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-…
The WeekBioPharma Dive ↗
Moderna's upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech's shares t…
The WeekPharmaceutical Technology ↗
The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $…
The WeekBioPharma Dive ↗
Results published in NEJM raised questions about the benefits "silencer" medications provide on top of standar…
The WeekPharmaceutical Technology ↗
The new Mounjaro approval will likely expand Lilly's cardiometabolic empire as it looks to stay ahead of rival…
The WeekPharmaVoice ↗
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug's third approved indica…
The WeekPharmaVoice ↗
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the…
The WeekFiercePharma ↗
Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningfu…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.